SDS3 Antibody

What is SDS3 and what cellular functions does it perform?

SDS3 (also known as SUDS3 or SAP45) is a regulatory protein that functions as a transcriptional repressor by augmenting histone deacetylase activity of HDAC1. It plays an essential role in chromatin remodeling and gene expression by modulating the structural conformation of chromatin, which affects DNA accessibility . SDS3 may have a potential role in tumor suppressor pathways through the regulation of apoptosis. Additionally, it functions in the assembly and enzymatic activity of the mSin3A corepressor complex, which is critical for transcriptional silencing .

What are the key structural domains of SDS3 that antibodies typically target?

SDS3 contains distinct functional domains that are frequently targeted by antibodies. Based on experimental studies, SDS3 can be divided into N-terminal and C-terminal regions, each with specific interaction capabilities. The C-terminal region of SDS3 has been shown to interact with regulatory proteins such as USP17, while different domains may be involved in other protein-protein interactions . When selecting SDS3 antibodies, researchers should consider which domain they wish to study, as this will affect experimental outcomes and interpretation.

How do I determine the appropriate SDS3 antibody for my specific research application?

Selection of an appropriate SDS3 antibody depends on your experimental application, target species, and specific research question. For Western blot analysis, monoclonal antibodies like EPR15000 have shown high specificity with a predicted band size of 38 kDa and observed band size of 45 kDa in human cell lines including Raji, HeLa, K562, and Molt-4 . For immunoprecipitation studies, antibodies that recognize native conformations are essential. When planning experiments:

Validate your antibody using positive controls such as Raji, HeLa, K562, or Molt-4 cell lysates, which have demonstrated reliable SDS3 expression .

What is the optimal protocol for SDS3 antibody-based Western blot analysis?

For optimal Western blot detection of SDS3, follow this methodological approach:

• Prepare cell lysates in a buffer containing 50 mM Tris (pH 7.6), 150 mM NaCl, 1 mM EDTA, and 1% Triton X-100, supplemented with protease inhibitor mixture .

• Load 20 μg of protein per lane on SDS-PAGE gel (10-12% is typically suitable).

• Transfer proteins to a PVDF or nitrocellulose membrane.

• Block with 5% non-fat milk in TBST for 1 hour at room temperature.

• Incubate with anti-SDS3 antibody (e.g., EPR15000) at 1:1000 dilution overnight at 4°C .

• Wash with TBST (3 × 5 minutes).

• Incubate with secondary antibody (e.g., Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugate) at 1:1000 dilution for 1 hour at room temperature .

• Wash with TBST (3 × 5 minutes).

• Develop using ECL detection reagent.

Note that the predicted band size for SDS3 is 38 kDa, but the observed band size is typically 45 kDa . This discrepancy is likely due to post-translational modifications such as ubiquitination .

How can I effectively perform co-immunoprecipitation to study SDS3 interactions?

To study SDS3 protein interactions through co-immunoprecipitation:

• Harvest cells and lyse in buffer containing 50 mM Tris (pH 7.6), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, supplemented with protease inhibitor mixture .

• Clear lysates by centrifugation (14,000 × g, 10 minutes, 4°C).

• Incubate cell lysates with anti-SDS3 antibody (approximately 2 μg) at 4°C overnight .

• Add 30 μl of protein A/G PLUS agarose and incubate at 4°C for 1 hour with rotation .

• Wash the immunoprecipitates with lysis buffer (4-5 times).

• Elute bound proteins by boiling in SDS sample buffer.

• Analyze by Western blotting with antibodies against suspected interacting proteins.

This method has successfully demonstrated interactions between SDS3 and proteins such as USP17, confirming their endogenous association in various cell types .

What approaches can I use to study SDS3 ubiquitination patterns?

To investigate SDS3 ubiquitination, particularly the Lys-63-specific polyubiquitination that has been documented:

• Transfect cells with vectors encoding FLAG-SDS3 and HA-tagged ubiquitin (wild-type or mutants like HA-R48K-ubiquitin, HA-R63K-ubiquitin for specific linkage analysis) .

• After 48 hours, lyse cells in buffer containing deubiquitinase inhibitors (e.g., N-ethylmaleimide).

• Immunoprecipitate SDS3 using anti-FLAG antibody.

• Analyze ubiquitination by Western blotting with anti-HA antibody to detect ubiquitin chains.

To study deubiquitination by USP17:

• Co-transfect cells with FLAG-SDS3, HA-ubiquitin, and either wild-type USP17 or catalytically inactive USP17 (C89S) .

• Proceed with immunoprecipitation and Western blotting as described above.

This approach has revealed that SDS3 undergoes Lys-63-specific polyubiquitination, which is regulated by the deubiquitinase USP17 .

How can I investigate the role of SDS3 in chromatin remodeling complexes?

To study SDS3's function in chromatin remodeling:

• Chromatin Immunoprecipitation (ChIP): Use SDS3 antibodies to identify genomic regions where SDS3-containing complexes bind. Follow standard ChIP protocols with anti-SDS3 antibodies.

• Sequential ChIP (Re-ChIP): To determine co-occupancy with other components of histone deacetylase complexes:

  • Perform initial ChIP with anti-SDS3 antibody

  • Elute the complexes

  • Perform a second round of ChIP with antibodies against other complex components (e.g., HDAC1, mSin3A)

• Functional genomics approaches:

  • Implement SDS3 knockdown using shRNA (target sequences: GAC ACT GAG GAT GCT AGT G or GCT AGA TCA GCA GTA CAA AG have been validated)

  • Analyze consequent changes in chromatin accessibility using ATAC-seq

  • Examine alterations in gene expression profiles using RNA-seq

This multi-faceted approach can provide insights into how SDS3 contributes to chromatin structure and transcriptional regulation in different cellular contexts .

What methodological approaches can help investigate the relationship between SDS3 ubiquitination and its function?

To explore how ubiquitination affects SDS3 function:

• Generate ubiquitination-deficient mutants:

  • Identify potential ubiquitination sites in SDS3

  • Create lysine-to-arginine mutants to prevent ubiquitination

  • Compare the activity of wild-type and mutant SDS3 in functional assays

• Manipulate ubiquitination/deubiquitination enzymes:

  • Overexpress or knock down USP17, which has been shown to specifically deubiquitinate SDS3

  • Monitor changes in SDS3 function and localization

• Differential functional analysis:

  • Compare chromatin association of ubiquitinated versus deubiquitinated forms of SDS3

  • Examine protein-protein interactions of each form

  • Assess transcriptional repression activity using reporter assays

Research has shown that SDS3 readily undergoes endogenous polyubiquitination, specifically Lys-63-branched polyubiquitination, which is regulated by USP17 . Understanding how this modification affects SDS3 function can provide insights into chromatin regulation mechanisms.

How do I design experiments to study SDS3's potential role in tumor suppressor pathways?

To investigate SDS3's role in tumor suppression:

• Expression analysis in cancer tissues:

  • Compare SDS3 expression levels between normal and cancerous tissues

  • Correlate expression with clinical outcomes using tissue microarrays and patient databases

• Functional studies:

  • Manipulate SDS3 expression in cancer cell lines through overexpression or knockdown

  • Assess changes in:

    • Proliferation rate

    • Apoptosis sensitivity

    • Cell cycle progression

    • Colony formation and migration capacity

• Mechanistic investigation:

  • Identify apoptotic pathways regulated by SDS3

  • Examine interactions with known tumor suppressor proteins

  • Investigate changes in gene expression profiles of cancer-related genes

Given that SDS3 may function in tumor suppressor pathways through regulation of apoptosis , these experimental approaches can help elucidate its specific role in cancer development and progression.

How should I interpret discrepancies in SDS3 detection between different antibodies?

When faced with discrepancies between different SDS3 antibodies:

• Consider epitope differences: Different antibodies may recognize distinct epitopes that could be masked by protein interactions or post-translational modifications. The C-terminal and N-terminal regions of SDS3 have different interaction patterns with other proteins .

• Evaluate detection conditions: Some antibodies perform optimally under denaturing conditions (Western blot), while others work best with native conformations (immunoprecipitation, immunofluorescence).

• Validation strategies:

  • Use multiple antibodies targeting different epitopes

  • Include positive controls (e.g., Raji, HeLa, K562, or Molt-4 cell lysates)

  • Implement genetic approaches (overexpression or knockdown) to confirm specificity

• Check for post-translational modifications: SDS3 undergoes polyubiquitination , which can affect antibody recognition. Consider using deubiquitinase inhibitors in your sample preparation.

What methodological approaches can help distinguish between specific and non-specific binding of SDS3 antibodies?

To ensure specificity in SDS3 antibody-based experiments:

• Include proper controls:

  • Isotype controls for monoclonal antibodies

  • Pre-immune serum for polyclonal antibodies

  • Blocking peptide competition assays

  • SDS3 knockdown or knockout samples

• Validation techniques:

  • Multiple antibodies against different epitopes should yield consistent results

  • Recombinant protein controls to confirm expected molecular weight

  • IP followed by mass spectrometry to confirm identity of detected proteins

• Stringency optimization:

  • Titrate antibody concentrations (1:500 to 1:2000 for Western blot)

  • Optimize washing conditions and buffers

  • Adjust blocking reagents to reduce background

When evaluating experimental results, remember that SDS3 typically appears at 45 kDa in Western blots, despite a predicted molecular weight of 38 kDa , which is likely due to post-translational modifications.

What analytical approaches can quantify changes in SDS3 localization and protein interactions?

To quantitatively assess SDS3 localization and interactions:

• For subcellular localization:

  • Perform fractionation followed by Western blot analysis

  • Use immunofluorescence with colocalization analysis software

  • Calculate Pearson's correlation coefficient or Manders' overlap coefficient to quantify colocalization with nuclear markers

• For protein interaction strength:

  • Implement quantitative IP followed by Western blot densitometry

  • Use proximity ligation assays (PLA) for in situ interaction detection

  • Consider FRET or BiFC for live-cell interaction studies

• Data analysis frameworks:

  • For immunofluorescence: Data-driven image analysis approaches similar to those used for other antibody studies can be adapted to quantify SDS3 localization patterns

  • For interaction studies: Pull-down assays with purified components can provide direct binding information

Studies have shown that SDS3 is predominantly expressed in the nucleus, where it also colocalizes with its interaction partner USP17 . Using these quantitative approaches can help determine how experimental conditions affect these patterns.

What strategies can resolve weak or inconsistent SDS3 signals in Western blot analyses?

When facing weak or inconsistent SDS3 detection:

• Sample preparation optimization:

  • Include deubiquitinase inhibitors in lysis buffer to preserve ubiquitinated SDS3

  • Optimize protein extraction protocol for nuclear proteins

  • Use fresh samples or proper storage conditions (-80°C with protease inhibitors)

• Technical adjustments:

  • Increase antibody concentration (try 1:500 instead of 1:1000)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Use enhanced sensitivity detection reagents

  • Consider membrane type (PVDF may provide better retention than nitrocellulose)

• Signal enhancement approaches:

  • Use signal amplification systems

  • Implement immunoprecipitation before Western blotting to concentrate the protein

  • Consider loading more total protein (30-50 μg instead of 20 μg)

SDS3 detection has been successful in multiple cell types including Raji, HeLa, K562, and Molt-4 cells , so using these as positive controls can help troubleshoot detection issues.

How can I improve the specificity and yield in SDS3 immunoprecipitation experiments?

To enhance SDS3 immunoprecipitation results:

• Optimization of lysis conditions:

  • Use buffer containing 50 mM Tris (pH 7.6), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100

  • Include complete protease inhibitor mixture to prevent degradation

  • For studying ubiquitination, add deubiquitinase inhibitors like N-ethylmaleimide

• Antibody selection and usage:

  • Use 2-5 μg of antibody per immunoprecipitation reaction

  • Pre-clear lysates with protein A/G beads before antibody addition

  • Incubate with antibody overnight at 4°C for complete binding

• Washing optimization:

  • Use at least 4-5 washes to reduce background

  • Consider including increasing salt concentrations in later washes

  • Monitor protein retention during wash steps

Using validated protocols, investigators have successfully demonstrated endogenous interaction between SDS3 and proteins such as USP17 through co-immunoprecipitation, confirming their biological relevance .